Novatio Ventures

Novatio targets early-stage life science companies, specifically seed, startup, and spin-off opportunities across therapeutics, medical devices, and diagnostics. The firm focuses on innovations originating in Canada, the US, China, and South Korea, deploying direct capital and operational resources to advance preclinical or early clinical assets toward value inflection.

Novatio embeds partners into portfolio companies as interim executives rather than solely relying on board-level oversight. Founders Peng Fu and Ben Walker hold active officer roles inside 3io Therapeutics, and the firm routinely structures spin-off entities, provides interim management, and leads licensing negotiations itself — effectively operating as a commercialization partner alongside seed capital.

Founder and General Partner Peng Fu leads investment decisions, supported by Managing Partner Christopher Kim and Partners Sandy Der and Ben Walker. The team’s combined experience spans royalty monetization, big pharma corporate development, academic research, and cross-border Asia–US biotech fund management.

Novatio operates from offices in Toronto, Cambridge (Massachusetts), and Hong Kong. The firm explicitly pursues innovations sourced from Canada, the US, China, and South Korea, with Mandarin fluency across several partners facilitating direct engagement in Chinese-language deal environments.